Publikationen, an denen er mitarbeitet ROSA QUILES PEREZ (14)

2021

  1. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

2018

  1. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry

    Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502

  2. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C

    Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948

2017

  1. Influence of HLA class I, HLA class II and KIRs on vertical transmission and chronicity of hepatitis C virus in children

    PLoS ONE, Vol. 12, Núm. 2

  2. The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response

    Scientific Reports, Vol. 7, Núm. 1

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

2013

  1. Importance of IL-10 and IL-6 during chronic hepatitis c genotype-1 treatment and their relation with IL28B

    Cytokine, Vol. 61, Núm. 2, pp. 595-601

2012

  1. Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer

    Molecular Carcinogenesis, Vol. 51, Núm. 8, pp. 608-618

  2. Plasma Ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients

    Journal of Clinical Gastroenterology, Vol. 46, Núm. 4, pp. 328-333

2011

  1. Hepatic expression of adiponectin receptors increases with non-alcoholic fatty liver disease progression in morbid obesity in correlation with glutathione peroxidase 1

    Obesity Surgery, Vol. 21, Núm. 4, pp. 492-500

  2. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin

    American Journal of Gastroenterology, Vol. 106, Núm. 7, pp. 1246-1254

2008

  1. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses

    Journal of Virology, Vol. 82, Núm. 13, pp. 6644-6653

  2. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin

    Journal of Clinical Virology, Vol. 41, Núm. 4, pp. 264-269